Comparison of two different methods for CA19-9 antigen determination

Clinical Laboratory

Volumn 56, Issue 7-8, 2010, Pages 319-325

  Deinzer, Martina ^a   Faissner, Ralf ^a   Metzger, Tobias ^a   Kaminski, Wolfgang E ^a   Löhr, Mathias ^a   Neumaier, Michael ^a   Brinkmann, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BECKMAN COULTER INC   (United States)

Author keywords

CA19 9 gastrointestinal cancer antigen; GI monitor, pancreatic cancer; Method comparison, diagnosis

Indexed keywords

CA 19-9 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PANCREAS CANCER; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CHEMISTRY; COMPARATIVE STUDY; IMMUNOASSAY; INSTRUMENTATION; METHODOLOGY; PANCREAS TUMOR; PANCREATITIS; REPRODUCIBILITY; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; CA-19-9 ANTIGEN; HUMANS; IMMUNOASSAY; PANCREATIC NEOPLASMS; PANCREATITIS; REPRODUCIBILITY OF RESULTS;

EID: 77957342871     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lillemoe KD, YEO CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 2000;50:241-68. (Pubitemid 30654881)
2. Steinberg W. The clinical utility of the CA19-9 tumour-associated antigen. Am J Gastroenterol 1990;85:350-5. (Pubitemid 20140602)
3. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumour-associated antigen CA19-9. Pancreas 1994;9:731-4. (Pubitemid 24317825)
4. Duffy MJ. CA19-9 as marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364-70. (Pubitemid 28230734)
5. Safi F, Roscher R, Beger HG. The clinical relevance of the tumour marker CA19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83-91. (Pubitemid 20048630)
6. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001;31:9-16. (Pubitemid 32012598)
7. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumour marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61. (Pubitemid 29036385)
8. Stern P, Friedecky B, Bartos V, et al. Comparison of different immunoassays for CA19-9. Clin Chem Lab Med 2001;39:1278-82.
9. Klapdor R, Bahlo M, Babinsky A. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumour marker determinations (CA19-9 / CEA). Anticancer Res 2005;25:1687-91. (Pubitemid 40896786)
10. Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugar-baker PH. Utility of CEA and CA19-9 tumour markers in diagnosis and prognosis assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004;87:162-6. (Pubitemid 39167382)
11. Massacesi C, Rocchi MB, Marcucci F, Pilone A, Galeazzi M, Bonsignori M. Serum tumour markers may precede instrumental response to chemotherapy in patients with metastatic cancer. Int J Biol Markers 2003;18:295-300.
12. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-7. (Pubitemid 37386593)
13. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41. (Pubitemid 36323101)
14. Ohara K, Tatsuzaki H, Molotkova NG, et al. Utility of serum CA19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology 2001;48:859-63. (Pubitemid 32619699)
15. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA19-9 serum levels in colorectal cancer. Anticancer Res 2000;20:5195-8. (Pubitemid 32319106)
16. Zucchelli GC, Pilo A, Chiesa MR, Cohen R, Bizollon CA. Growing use of nonisotopic CA19-9 immunoassays increases between laboratory variability. Clin Chem 1993;39:909-11. (Pubitemid 23145696)
17. Rye PD, Bovin NV, Vlasova EV, et al. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against sialyl Lewis a and related antigens. Montreux, Switzerland, September 19-24, 1997. Tumour Biol 1998;19:390-420. (Pubitemid 28384465)
18. Plebani M, Giacomini A, Beghi L, et al. Serum tumour markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996;16:2249-52. (Pubitemid 26265573)
19. Yagmur E, Müller R, Driesch R, Gressner AM. Analytical performance of Beckman Coulter GI (CA19-9 Antigen) Monitor immunoassay. Clin Chem Lab Med 2004;42(10):A07.
20. Matalliotakis IM, Goumenou AG, Mulayim N, Karkavitsas N, Koumantakis EE. High concentrations of the CA-125, CA19-9 and CA 15-3 in the peritoneal fluid between patients with and without endometriosis. Arch Gynecol Obstet 2005;271:40-5. (Pubitemid 40174576)
21. Stieber P, Molina R, Gion M, et al. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 immunoassay system. Clin Chem Lab Med 2008;46:600-11. (Pubitemid 351749108)